You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

ansaid Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Ansaid patents expire, and what generic alternatives are available?

Ansaid is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in ANSAID is flurbiprofen. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the flurbiprofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ansaid

A generic version of ansaid was approved as flurbiprofen by TEVA on May 31st, 1995.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ansaid?
  • What are the global sales for ansaid?
  • What is Average Wholesale Price for ansaid?
Summary for ansaid
Drug patent expirations by year for ansaid
Recent Clinical Trials for ansaid

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerPhase 1
United States Army Research Institute of Environmental MedicinePhase 1
National Institute of Dental and Craniofacial Research (NIDCR)Phase 2

See all ansaid clinical trials

US Patents and Regulatory Information for ansaid

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn ANSAID flurbiprofen TABLET;ORAL 018766-002 Oct 31, 1988 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pharmacia And Upjohn ANSAID flurbiprofen TABLET;ORAL 018766-003 Oct 31, 1988 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ansaid

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn ANSAID flurbiprofen TABLET;ORAL 018766-002 Oct 31, 1988 ⤷  Sign Up ⤷  Sign Up
Pharmacia And Upjohn ANSAID flurbiprofen TABLET;ORAL 018766-003 Oct 31, 1988 ⤷  Sign Up ⤷  Sign Up
Pharmacia And Upjohn ANSAID flurbiprofen TABLET;ORAL 018766-003 Oct 31, 1988 ⤷  Sign Up ⤷  Sign Up
Pharmacia And Upjohn ANSAID flurbiprofen TABLET;ORAL 018766-002 Oct 31, 1988 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ansaid

See the table below for patents covering ansaid around the world.

Country Patent Number Title Estimated Expiration
Denmark 127251 ⤷  Sign Up
Denmark 116794 ⤷  Sign Up
Germany 1518528 ⤷  Sign Up
Switzerland 454822 Procédé de préparation d'acides carboxyliques thérapeutiquement actifs ⤷  Sign Up
Netherlands 6500865 ⤷  Sign Up
Switzerland 501577 Procédé de préparation d'acides phénylalcanoïques thérapeutiquement actifs (Biphenyl derivs antipyretic - analgesic antiinflammatory) ⤷  Sign Up
Sweden 329843 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.